Сывороточный уровень растворимых форм мембранных антигенов клеток иммунной системы при вирусных гепатитах B, C и G
Диссертация
Изучение сывороточного уровня SCD50 антигена у больных острой формой вирусного гепатита С на протяжении всего курса лечения также не выявило достоверных отличий от нормы. И в этом случае вирусная инфекция сопровождалась широким разбросом индивидуальных значений sCD50 антигена. Относительное содержание CD50+ положительных мононуклеарных клеток периферической крови при HCV-инфекции не менялось… Читать ещё >
Список литературы
- Аббасова С.Г., Липкин В. М., Трапезников Н. Н. и др. Система FAS FASL в норме и патологии. // Вопр. биол., мед., фарм. химии. — 1999. — № 3. — С. 317.
- Алясова А.В., Королева В. В., Крыжанова М. А. Исследование содержания растворимых антигенов CD38, CD25, CD18 у больных лимфогранулематозом. // Клиническая лабораторная диагностика. 2000. — № 9. — С. 40.
- Алясова А.В., Королева В. В., Крыжанова М. А. Растворимая форма CD38 антигена в иммунологическом мониторинге лимфогранулематоза. // Аллергология и иммунология: Тез. докл. Ill съезда иммунологов и аллергологов СНГ. 2000. — Т. 1. — № 2. — С. 167−168.
- Балаян М.С., Михайлов М. И. Энциклопедический словарь вирусные гепатиты. — М.: Амипресс. — 1999. — 302 с.
- Барышников А.Ю., Тоневицкий А. Г. Моноклональные антитела в лаборатории и клинике. М.: Медицина. — 1997. -212 с.
- Воробьев В.Г., Новиков В. В., Лебедева А. И. Иммунодиагностика острых лейкозов. Нижний Новгород: Изд-во НГМА. — 1998. — С. 8.
- Вязьмина Е.С. Особенности иммунного ответа организма на Treponema Pallidum. Автореф. канд. дисс. — Москва. — 2002. — 22 с.
- Вязьмина Е.С., Фриго Н. В., Комарова В. Д. и др. Сравнительное исследование уровня растворимых форм CD50 и CD95 антигенов в сыворотке крови больных сифилисом. // Материалы XII конференции «Ферменты микроорганизмов». Казань. — 2001. — С. 73−74.
- Гланц С. Медико-биологическая статистика. М.: Практика. — 1999. -450 с.
- Егоров A.M., Осипов А. П., Дзантиев Б. Б. и др. Теория и практика имму-ноферментного анализа. М.: Высшая школа. — 1991. — 288 с.
- Лебедев М.Ю., Крыжанова М. А., Кораблев С. Б. и др. Растворимый CD38 антиген информативный показатель состояния иммунной системы при ожоговой болезни. // Нижегородский медицинский журнал. — 2000. — № 2. — С. 1014.
- Меньшиков В.В. Лабораторные методы исследования в клинике. М. -1987. — С. 179.
- Михайлов М.И. Гепатит G проблемы изучения. // Вирусные гепатиты: достижения и перспективы. — 1997. — № 1. — С. 3−11.
- Никонова М.Ф., Литвина М. М., Варфоломеева М. И. и др. Апоптоз и пролиферация как альтернативные формы ответа Т-лимфоцитов на стимуляцию. // Иммунология. 1999. — № 2. — С. 20−23.
- Новиков В.В. Диагностическая значимость при вирусных инфекциях мембранных и растворимых форм дифференцировочных антигенов клеток иммунной системы. // Гематология и трансфузиология. 1996. — № 6. — С. 40−43.
- Новиков В.В. Характеристика и биотехнология моноклональных антител против лимфоцитарных антигенов. Автореф. докт. дисс. — М. — 1994. — 48 с.
- Новиков В.В., Алясова А. В., Варшавская Л. В. и др. Прогностическое значение уровня растворимого CD38 антигена при раке молочной железы. // Аллергология и иммунология. М. — 2001. — Т. 2. — № 2. — С. 116.
- Новиков В.В., Барышников А. Ю. Растворимые формы мембранных белков клеток иммунной системы как компоненты глобальной иммунологической сети. // Тезисы научн. докладов III Съезда биохимического общества. -С.-Пб. 2002. — С. 196−197.
- Новиков В.В., Трофимова М. Н., Андреев А. В. и др. Очистка моноклональных антител с помощью стафилококкового реагента, содержащего белок А. //Лабораторное дело. 1987. — № 6. — С. 606−610.
- Новиков В.В., Трофимова М. Н., Жильцова М. А. и др. Сравнение действия иристана и неполного адъюванта Фрейнда на формирование асцита мышей-носителей гибридомных клеток. // Антибиотики и химиотерапия.1988. № 7. — С. 530−532.
- Онищенко Г. Г. Материалы к докладу на VIII Всероссийском съезде эпидемиологов, микробиологов и паразитологов. // Мир вирусных гепатитов. -2002. -№ 14.-С. 2−4.
- Полак Д., Норден С. В. Введение в иммуноцитохимию: современные методы и проблемы. М.: Мир. — 1987. — С. 23−27.
- Ройт А., Бростофф Дж., Мейл Д. Иммунология. М.: Мир. — 2000. — 592 с.
- Рыжов С.В., Новиков В. В., Молекулярные механизмы апоптоза. // Российский биотерапевтический журнал. 2002. — № 3. — С. 27−33.
- Семененко Т.А. Клеточный иммунный ответ при гепатите С. И Вирусные гепатиты: Достижения и перспективы. 2000. — № 1. — С. 3−10.
- Соринсон С.Н. Вирусные гепатиты. С.-Пб.: ТЕЗА. — 1997. — 306 с.
- Фримель Г. Иммунологические методы. М.: Медицина. — 1987. — 472 с.
- Хаитов P.M., Алексеев Л. П. Физиологическая роль главного комплекса гистосовместимости человека. // Иммунология. 2001. — № 3. — С. 4−12.
- Хлопова И.Н., Быченко Д. В., Самохвалов Е. И. Влияние вируса гепатита G на течение острого гепатита В и С. // Вопросы вирусологии. 1999. — № 2. — С. 265−268.
- Abrignahi S. Cellular immune reactions against hepatitis С core antigen in chronic hepatitis C. // Gastroenterology. 1995. — Vol. 108. — № 6. — P. 19 571 958.
- Acevedo A., del Pozo M.A., Arroyo A.G. et al. Distribution of ICAM-3 beaming cells in normal human tissues. Expression of a novel counter-receptor for LFA-1 in epidermal Langerhans cells. // Am. J. Pathol. 1993. — Vol. 143. — P. 774−783.
- Ahmed R., Gray D. Immunological memory and protective immunity: understanding their relation. // Science. 1996. — Vol. 272. — P. 54−60.
- Al-Maini M.H., Mountz J.D., Al-Mohri H.A. et al. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. // Lupus. -2000. Vol. 9. — № 2. — P. 132−139.
- Alter M.J., Gallaher M., Morris T. et al. Acute non-A-E hepatitis in the United States and the role hepatitis G virus infection. // New Engl. J. of Medicine. -1997.-Vol. 336.-P. 741−746.
- Antonaci S., Jirillo E., Schiraldi O. Soluble HLA class I antigens in chronic hepatitis C: a disease-associated manifestation or molecules modulating immu-noresponsiveness? II Immunopharmacol. Immunotoxicol. 1999. — Vol. 21. — № 4. — P. 727−738.
- Baldwin R.L., Tran H., Karlan B.Y. Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. // Gynecol. Oncol. -1999. Vol. 74. — № 2. -P. 265−271.
- Bell H., Simmonds P., Helium K. et. al. Treatment of infection with hepatitis G virus/GBV-C with interferon alfa. // J. of Hepatology. 1997. — Vol. 1. — № 26. -P. 203.
- Bijl M., Lopik Т., Limburg P.C. et al. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus? // J. Autoimmun. 1998. — Vol. 11. — № 5. — P. 457−463.
- Bleijs D.A., Geijtenbeek T.B., Figdor C.G. et al. DC-SIGN and LFA-1: a battle for ligand. // TRENDS in Immunology. 2001. — Vol. 22. — № 8. — P. 457−463.
- Boni CM Bertoletti A., Penna A. et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. // J. Clin. Invest. 1998. — Vol. 102. — P. 968−975.
- Bresciani A., Pirozzi G., Spera M. et. al. Increased level of serum HLA class I antigens in patients with systemic lupus erythematosus. Correlation with disease activity. // Tissue Antigens. 1998. — Vol. 52 — № 1. — P. 44−50.
- Brieva J.A., Villar L.M., Leoro G. et al. Soluble HLA class I antigen secretion by normal lymphocytes: relationship with cell activation and effect of interferon-gamma. // Clin. Exp. Immunol. 1990. — Vol. 82. — № 2. — P. 390−395.
- Bromley S.K., Burack W.R., Johnson K.G. et al. The immunological synapse. // Annu. Rev. Immunol. 2001. — Vol. 19. — P. 375−396.
- Carbone E., Terrazzano G., Colonna M. et al. Natural killer clones recognize specific soluble HLA class I molecules. // Eur. J. Immunol. 1996. — Vol. 26. — № 3. — P. 683−689.
- Cascino I., Fiucci G., Papoff G. et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. // The Journal of Immunology. 1995. — Vol. 154. — P. 2706−2713.
- Chang K.M., Rehermann В., Chisari F.V. Immunopathology of hepatitis C. // Springer Semin. Immunopathol. 1997. — Vol. 19. — P. 57−68.
- Charles A., Janeway Jr., Travers P. et. al. Immunobiology. London: Current Biology Ltd. — 1994. — P. 222 — 227.
- Chemin J., Vermot-Desroches C., Baginski I. et al. Selective detection of human hepatitis В virus surface and core antigens in peripheral blood mononuclear cell subsets by flow cytometry. // J. of Viral Hepatitis. 1994. — Vol. 2. — № 2. -P. 91−97.
- Colombatto P., Randone A., Civico G. et al. Hepatitis G virus RNA in the serum of patients with elevated gamma glutamyl transpeptidase and alkaline phosphatase: a specific liver disease. II J. of Viral Hepatitis. 1996. — Vol. 3. -P. 301−306.
- Contini P., Ghio M., Merlo A. et al. Soluble HLA class I/CD8 ligation triggers apoptosis in EBV CD8(+) cytotoxic T lymphocytes by Fas/Fas-ligand interaction. II Hum. Immunol. 2000. — Vol. 61. — № 12. — P. 1347−1351.
- Cooper S., Erickson A., Adams E. et al. Analysis of a successful immune response against hepatitis С virus. // Immunity. 1999. — Vol. 10. — P. 439−449.
- Cramp M.E., Carucci P., Rossol A. et al. Hepatitis С virus (HCV) specific immune response in anti-HCV positive patients without hepatitis С viraemia. // Gut.- 1999. Vol. 44. — P. 424−429.
- Crespo J., Rivero M., Mayorga M. et al. Involvement of the fas system in hepatitis С virus recurrence after liver transplantation. // Liver Transpl. 2000. -Vol. 6. — № 5. — P. 562−569.
- Deaglio S., Dianzani U., Horenstein A.L. et al. Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. // J. Immunol. -1996.-Vol. 156.-P. 727−734.
- Deaglio S., Mehta K., Malavasi F. Human CD38: a ®evolutionary story of enzymes and receptors. // Leukemia Research. 2001. — Vol. 25.- P. 1−12.
- Deaglio S., Morra M., Mallone R. et al. Human CD38 (ADP ribosyl cyclase) is a counter-receptor of CD31, an Ig superfemily member. II J. Immunol. 1998. -Vol. 160.-№ 1.-P. 395−402.
- Diepolder H.M., Zachoval R., Hoffmann R.M. et al. The role of hepatitis С virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. // J. Mol. Med.- 1996. Vol. 74. — P. 583−588.
- Duran 1., Martinez-Caceres E.M., Rio J. et al. Immunological profile of patients with primary progressive multiple sclerosis. // Brain. 1999. — Vol. 122. -P. 2297−2307.
- Faubion W.A., Gores G.J. Death receptor in liver biology and pathobiology. // Hepatology. 1999. — Vol. 29. — P. 1−4.
- Filaci G., Contini P., Brenci S. et al. Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluids of multiple sclerosis patients. // Hum. Immunol. 1997. — Vol. 54. — № 1. — P. 54−62.
- Flora A., Franco L., Guida L. et al. Ectocellular CD38-catalysed synthesis and intracellular Ca (2+)-mobilizing activiity of cyclic ADF-ribose. // Cell Biochem. Biophys. 1998. — Vol. 28. — № 1. — P. 45−62.
- Funaro A., Horenstein A.L., Calosso L. et al. Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids. // International Immunology. 1996. — Vol. 8. — № 11. — P. 1643−1650.
- Funaro A., Morra M., Calosso L. et al. Role of the human CD38 molecule in В cell activation and proliferation. // Tissue Antigens. 1997. — Vol. 49. — P. 715.
- Fushimi M., Furukawa F., Tokura Y. et al. Membranous and soluble forms of Fas antigen in cutaneous lupus erythematosus. //J. Dermatol. 1998. — Vol. 25. — № 5. — P. 302−308.
- Ghio M., Contini P., Mazzei C. et al. Soluble HLA class I, HLA class II, and Fas Ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. // Blood. 1999. — Vol. 93. — № 5. -P. 1770−1777.
- Giacomelli R., Passacantando A., Parzanese I. et al. Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Cronhn s disease (CD). // Clin. Exp. Immunol.-1998.-Vol. 111. № 3. — P. 532−535.
- Griffitths C.E., Boffa M.J., Gallatin W.M. et al. Elevated levels of circulating intercellular adhesion molecule-3 (clCAM-3) in Psoriasis. // Acta Derm. Venereol. 1996. — Vol. 76. — № 1. — P. 2−5.
- Grimaldi H. M., Bazan J.С., Lund J. et al. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. // Science. 1993. — Vol. 262.-P. 1056.
- Gruner N.H., Gerlach T.J., Jung M.C. et al. Association of hepatitis С virus-specific CD8+ T cells with viral clearance in acute hepatitis C. // J. Infect. Dis. -2000. Vol. 181. — № 5. — P. 1528−1536.
- Guidotti L.G., Rochford R., Chung J. et al. Viral clearance without destruction of infected cells during acute HBV infection. // Science. 1999. — Vol. 284. — P. 825−829.
- Hagihara M., Shimura Т., Takebe K. et al. Serum concentrations of soluble HLA class I and CD8 forms in patients with viral hepatic disoders. // J. Gastroenterol. — 1997. — Vol. 32. — № 3. — P. 338−343.
- Hayashi N., Mita E. Fas system and apoptosis in viral hepatitis. // J. Gastroenterol. Hepatol. 1997. — Vol. 12. — P. 223−226.
- Haydon G.H., Jarvis L., Simpson K.J. et al. The clinical significance of the detection of hepatitis GBV-C RNA in the serum of patients with fulminant, presumed viral hepatitis. // J. Viral. Hepatit. 1997. — Vol. 4. — P. 45−49.
- Heaney M.L., Golde D.W. Soluble cytokine receptors. // Blood. 1996. — Vol. 87. — № 3. — P. 847−857.
- Hoffmann J.C., Bahr M.J., Tietge U.F. et al. Detection of a soluble form of the human adhesion receptor lymphocyte function-associated-antigen-3 (LFA-3) in patients with chronic liver desease. // J. Hepatol. 1996. — Vol. 25. — P. 465−473.
- Horenstein A.L., Stockinger H., Imnof B.A. et al. CD38 binding to human myeloid cells is mediated by mouse and human CD31. // Biochem. J. 1998. -Vol. 330.-P. 1129−1135.
- Hosaka N., Oyaizu N., Than S. et al. Correlation of loss of CD4 T cells with plasma levels of both soluble form Fas (CD95) Fas ligand (FasL) in HIV-infected infants. // Clin. Immunol. 2000. — Vol. 95. — № 1. — P. 20−25.
- Hosaka S., Shah M.R., Pope R.M. et al. Soluble forms of P-selectin and intercellular adhesion molecule-3 in synovial fluids. // Clin. Immunol. Immunopa-thol. 1996. — Vol. 78. — № 3. — P. 276−282.
- Inchauspe G. Protection and defence mechanisms in HCV infection. // Nephrol. Dial. Transpl.-1996.-Vol. 11.-P. 6−8.
- Inostroza J., Ferrada J., Navarrete C. et al. Soluble histocompatibility class I antigens and beta 2-microglobulin in pregnant females and cord blood samples. // Hum. Immunol. 1997. — Vol. 54. — № 1. — P. 63−68.
- Inostroza J., Munoz P., Espinoza R. et al. Quantitation of soluble HLA class I heterodimers and beta 2-microglobulin in patients with active pulmonary tuberculosis. // Hum. Immunol. 1994. — Vol. 40. — № 3. — P. 179−182.
- Inoue S., Kontani K., Tsujimoto N. et al. Protein-tyrosine phosphorylation by lgG1 subclass CD38 monoclonal antibodies is mediated through stimulation of the Fcyll receptors in human myeloid cell lines. //J. Immunol. 1997. — Vol. 159. — P. 5226−5232.
- Jackson D.G., Bell J.I. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. // J. Imunol. 1990. — Vol. 144. -P. 2811.
- Jodo S., Kobayashi S., Nakajima Y. et al. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. // Clin. Exp. Immunol. -1998.-Vol. 112.-№ 2.-P. 166−171.
- Kaplanski G., Farnarier К., Payan M. et al. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. // Digestive and Sciences. 1997. — Vol. 42. — № 11. — P. 2277−2284.
- Khoo K.M., Chang C.F. Characterisation and localization of CD38 in the vertebrate eye. // Brain Res. 1999. — Vol. 821. — P. 17−25.
- Kitanaka A., Suzuki Т., Ito C. et al. CD38-mediated signaling events in murine pro-B cells expressing human CD38 with or without its cytoplasmic domain. //J. Immunol.-1999.-Vol. 162.-P. 1952−1958.
- Kleinman S. Hepatitis G virus biology, epidemiology, and clinical manifestations: Implications for blood safety. // Transfus. Med. Rev. 2001. -Vol. 15.-№ 3.-P. 201−212.
- Knipping E., Debatin K.-M., Striker K. et al. Identification of soluble APO-1in supernatans of human Band T-cell lines and increased serum levels in B- and T-cell leukemias. // Blood. 1995. — Vol. 85. — P. 1562−1569.
- Knolle P.A., Eckardt A.J., Protzer-Knolle U. et al. Circulating ICAM-1(sCD54) and LFA-3 (sCD58) in chronic hepatitis В A longitudinal study in patients treated with interferon-alpha. // Z. Gastroenterol. — 1997. — Vol. 35. — № 6. — P. 459−467.
- Koelman C.A., Ensink W., Mulder A. et al. Anti-HLA antibodies interfere in the detection of soluble HLA class I molecules. // Hum. Immunol. 1999. — Vol. 60. -№ 5.-P. 414−423.
- Koziel M.G., Walker B.D. Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis С virus infection. // Springer Semin. Im-munopathol. 1997. — Vol. 19. — P. 69−83.
- Krams S.M., Fox S.K., Beatty P.R. et. al. Human hepatocytes produce an isoform of FAS that inhibits apoptosis. // Transplantation. 1998. — Vol. 65. — P. 713−721.
- Laemmly U.K. Cleavage of structural protein during the assembly of the head of bacteriophage T4. // Nature. 1970. — Vol. 227. — № 4258. — P. 680−685.
- Lefrere J.J., Mariotti M., Lerable J. et al. Long-term persistence of hepatitis G virus in immunocompetent patients. // The Lanset. 1996. — Vol. 348. — P. 427 428.
- Levacher M., Hulstaer F., Tallet S. et al. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrom: staining and prognostic value. // Clin. Exp. Immunol. 1992. — Vol. 90. — P. 376.
- Liem L.M., Koelman C.A., Doxiadis I.I. et al. Elevated serum HLA class I levels coincide with acute and chronic graft-versus-host desease. // Bone Marrow Transplant. 1997. — Vol. 20. — № 3. — P. 227−234.
- Lim M.V., Fry K., Yun A. et al. Sequence variation and phylogenetic analysis of envelope glycoprotein of hepatitis G virus // J. Gen. Virol. 1997. — Vol. 78. -P. 2771−2777.
- Linnen J., Wages J., Zhang-Keck Z. et al. Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent. // Science. -1996.-Vol. 271.-P. 505−508.
- Lund F.E., Cockayne D.A., Randall T.D. et al. CD38: a new paradigm in lymphocyte activation and sigmal trunsduction. // Immunol. Rev. 1998. — Vol. 161. — P. 79−93.
- Lund F.E., Yu N., Kim K.M. et al. Signaling through CD38 augments В cell antigen receptor (BCR) responses and is dependent on BCR expression. // J. Immunol. 1996. — Vol. 157. — P. 1455−1467.
- Maini M.K., Bertoletti A. How can the cellular immune response control hepatitis В virus replication? // Journal of Viral Hepatitis. 2000. — Vol. 7. — № 5. -P. 321.
- Maini M.K., Boni C., Ogg G.S. et al. Direct ex vivo analysis of hepatitis В virus-specific CD8(+) T cells associated with the control of infection. // Gastroenterology. 1999.-Vol. 117.-№ 6-P. 1386−1396.
- Malaguamera M., Restuccia S., Di Fazio I. et al. Serum p2 microglobulin in chronic hepatitis C. // Dig. Dis. Sci. — 1997. — Vol. 42. — № 4. — P. 762−766.
- Malavasi F., Funaro A., Rogerro S. et al. Human CD38: a glycoprotein in search of a function. // Immunol. Today. 1994. — Vol. 15. — P. 95−97.
- Mallone R., Ferrua S.(Morra M. et al. Characterization of a CD38-like 78-kilodalton soluble protein released from В cell lines derived from patients with X-linked agammaglobulinemia. // J. Clin. Invest. 1998. — Vol. 101. — № 12. — P. 2821−2830.
- Martin S., Rieckmann P. et al. Circulating forms of ICAM-3 (clCAM-3). Elevated levels in autoimmune diseases and lack of association with clCAM-1. // J. Immunol. 1995. — Vol. 154. — № 4.- P. 1951−1955.
- Mastroianni C.M., Lichtner M. et al. Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients. //Clin. Immunol. -2000. Vol. 95. — № 3. — P. 212−217.
- Matsuura H., Jimbo S., Miyamura M. et al. A study of the association between HLA phenotype and serum concentration of soluble HLA class I. // Nihon Rinsho Meneki Gakkai Kaishi. 1997. — Vol. 2. — P. 102−107.
- McMillan R.W., Gelder F.B., Zibari G.B. et al. Soluble fraction of class I human histocompatibility leukocyte antigens in the serum of liver transplant recipient. // Clin. Transplant. 1997. — Vol. 11. — № 2. — P. 98−103.
- Mehta K., Malavasi F. Human CD38 and related molecules. Basel: Karger. -2000.-P. 99−116.
- Migliaresi S., Bresciani A., Ambrosone L. et al. Increased serum concentrations of soluble HLA- class I antigens in hepatitis С virus related mixed cryo-globulinaemia. // Ann. Rheum. Dis. 2000. — Vol. 59. — № 1. — P. 20−25.
- Milich D.R., Chen M.K., Hughes J.L. et al. The secreted hepatitis В precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. //J. Immunol. 1998. — Vol. 160. — P. 2013−2021.
- Minguela A., Torho A., Marhn L. et al. Implication of soluble and membrane HLA class I and serum IL-10 in liver graft acceptance. // Hum. Immunol. 1999. -Vol. 60. — № 6. — P.500−509.
- Mondelli M.U. Is there a role for immune response in the pathogenesis of hepatitis C? // J. Hepatology. 1996. — Vol. 25. — P. 232−281.
- Moore C., Ehlayel M., Inostrosa J. et al. Elevated levels of soluble HLA class I (sHLA-l) in children with sever atopic dermatitis. // Ann. Allergy Asthma Immunol. 1997. — Vol. 79. — № 2. — P. 113−118.
- Morra M., Zubiaur M., Terhorst C., Sancho J. et al. CD38 is functionally dependent on the TCR/CD3 complex in human T cells. // FASEB J. 1998. — Vol. 12. -№ 7.-P. 581−592.
- Munker R., Younes A., Cabanillas F. et al. Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. // Leuk. Lymphoma. 1997. — Vol. 21.- № 5−6. — P. 517−521.
- Musso Т., Deaglio S.(Franco L., et al. CD38 expression and functional activities are upregulated by IFN- on human monocytes and monocytic cell lines. //J. Leukoc. Biol.-2001.-Vol. 69. P. 605−612.
- Nakatsuji YM Wai-Kuo S.J., Tanaka J. et al. Prevalence and disease associated of hepatitis G virus infection in Japan. // J. of Hepatology. 1996. — Vol. 3. -P. 307−316.
- Naoumov N.V., Eddleston A.L. Host immune response and variations in the virus genom: Pathogenesis of the liver damage caused by hepatitis В virus. // Gut. 1994. — Vol. 35. — № 8. — P. 1013−1017.
- Nelson D.R., Marousis C.G., Davis G.L. The role of hepatitis С virus-specific cytotoxic T lymphocytes in chronic hepatitis. // J. Immunol. 1997. — Vol.158. -P. 1473−1481.
- Niitsu N., Sasaki K., Umeda M. A. High serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. // Leukemia. 1999. — Vol. 13. — № 9. — P. 1434−1440.
- Nocito M., Montalban C., Gonzalez-Porque P. et al. Increased soluble serum HLA class I antigens in patients with lymphoma. // Hum. Immunol. 1997. — Vol. 58.- № 2.-P. 106−111.
- Okuyama M., Yamaguchi S., Nozari N. et al. Serum levels of soluble forms of Fas molecule in patients with congestive heart failure. // Amer. J. Cardiol. -1997.-Vol. 79.-№ 12.-P. 1698−1701.
- Ott M.(Seidl С., Westhoff U. et al. Soluble HLA class I and class II antigens in patients with multiple sclerosis. // Tissue Antigens. 1998. — Vol. 51. — № 3. -P. 301−304.
- Papoff G., Cascino I., Eramo A. et al. An terminal domain shared by Fas/Apo-1 (CD95) soluble variant prevents cell death in vitro. // The Journal of Immunology. 1996. — Vol. 25. — P. 4625−4630.
- Pasqinelli C., Shoenberger J.M., Chung J. et al. Hepatitis С virus core and E2 protein expression in transgenic mice. // Hepatology. 1997. — Vol. 25. — № 3. -P. 719−728.
- Peter M.E., Krammer P.H. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. // Current Opinion in Immunology. 1998. — Vol. 10. — P. 545−551.
- Pfister M., Ogilvie A., Silva C.P. et al. NAD degradation and regulation of CD38 expression by human monocytes/macrophages. // European Journal of Biochemistry. 2001. — Vol. 268. — № 21. — P. 5601−5611.
- Piazzolla G., Tortorella C., Fiore G. et al. Immunoresponsiveness in chronic hepatitis patients: correlation between tissue and serum findings. // Immuno-pharmacol. Immunotoxicol. 1998. — Vol. 20. — № 3. — P. 337−354.
- Pinkoski M.J., Brunner Т., Green D. R. et al. Fas and Fas ligand in gut and liver. // Am. J. Physiol. Gastrointest. Liver Physiol. 2000. — Vol. 278. — P. 354 366.
- Plaeger S., Bass H.Z., Nishanian P. et al. The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes. // Clin. Immunol. 1999. — Vol. 90. — № 2. — P. 238 246.
- Ploegh H.L. Viral strategies of immune evasion. // Science. 1998. — Vol. 280. — P. 248−253.
- Pouletty P., Ferrone S., Amesland F. et al. Summary report from the fist international workshop on soluble HLA antigens. // Tissue Antigens. 1993. — Vol. 42. -№ 1. -P. 45−54.
- Pozo M.A., Pulido R., Munoz C. et al. Regulation of ICAM-3 (CD50) membrane expression on human neutrophils through a proteolytic shedding mechanism. // Eur. J. Immunol. 1994. — Vol. 24. — P. 2586−2594.
- Puppo F., Brenci S., Lanza L. et al. Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. // Hum. Immunol. -1994. Vol. 40. — № 4. — P. 259−266.
- Puppo F., Contini P., Ghio M. et al. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8+ Fas (CD95)+T lymphocytes. // International Immunology. 2000. — Vol. 12. — № 2. -P. 195−203.
- Puppo F., Picciotto A., Brenci S. et al. Behavior of soluble HLA class I antigens in patients with chronic hepatitis С during interferon therapy: an early predictor marker of response? // J. Clin. Immunol. 1995. — Vol. 15. — № 4. — P. 179−184.
- Rambusch E.G., Wedemeyer H., Tillmann H.L. et al. Significance of coinfection with hepatitis G virus for chronic hepatitis С a review of the literature. //Z. Gastroenterol. — 1998. — Vol. 36. — № 1. — P. 41−53.
- Rehermann В., Lau D., Hoofnagle J.H. et al. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis В virus infection. // J. Clin. Invest. 1996. — Vol. 97. — P. 1655−1665.
- Rhynes V.K., McDonald J.C., Gelder F.B. et. al. Soluble HLA class I in the serum of transplant recipients. // Ann. Surg. 1993. — Vol. 217. — № 5. — P. 485 489.
- Rieux-Laucat F., Deist F.L., Hivroz C. et al. Mutations in Fas associated with human lymphoproliferative syndrom and autoimmunity. // Science. 1995. -Vol. 268.-P. 1347−1349.
- Rokita E., Menzel E.J. Characteristics of CD14 shedding from human monocytes. Evidence for the competition of soluble CD14 (sCD14) with CD14receptors for lipopolysaccharide (LPS) binding. 11 APMIS. 1997. — Vol. 105. -№ 7.-P. 510−518.
- Romano L., Tanzi E., Chisotti D. et al. HEV and GBV-C infection in acute non A-C hepatitis in Italy. // Hepatology. 1997. — Vol. 26. — P. 192.
- Ryo K., Kamogawa Y., Ikeda I. et al. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. // Am. J. Gastroenterol. 2000. -Vol. 95. — № 8. — P. 2047−2055.
- Sacco R., Leuci D., Tortorella C. et al. Transforming growth factor betal and soluble Fas serum levels in hepatocellular carcinoma. // Cytokine. 2000. — Vol. 12.-№ 6.-P. 811−814.
- Sagnelli E., Coppola N., Scolastico C. et al. Virologic and clinical expressions of reciprocal inhibitori effect of hepatitis В, С and delta viruses in patients with chronic hepatitis. II Hepatology. 2000. — Vol. 32. — № 5. — P. 1106−1110.
- Sallie R., Shew J., Mtimer D. GBV-C virus and fulminant hepatic failure. // Lancet. 1996. — Vol. 347. — P. 1552−1555.
- Sano H., Asano K., Minatoguchi S. et al. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis. // Nephron. 1998. — Vol. 80. — № 2. — P. 153−161.
- Savarino A., Pugliese A., Martini C. et al. Investigation of the potential role of membrane CD38 in protection against cell death induced by HIV-1. // J. Biol. Regul. Homeost. Agents. 1996. — Vol. 10. — № 1. — P. 13−18.
- Sayegh M.H., Carpenter C.B. Role of indirect allorecognition in allograft rejection. II Int. Rev. Immunol. 1996. — Vol. 13. — P. 221−222.
- Sconocchia G., Titus J.A., Mazzoni A. et al. CD38 triggers cytotoxic responses in activated human natural killer cells. // Blood. 1999. — Vol. 94. — P. 3864−3871.
- Seeger C., Mason W. S. Hepatitis В Virus Biology. // Microbiology and Molecular Biology Reviews. 2000. — Vol. 64. — № 1. — P. 51−68.
- Shih C.M., Lo S.J., Miyamura T. et al. Supression of hepatitis В virus expression and replication by hepatitis С virus core protein in HuH-7 cells. // J. Virol. -1993. Vol. 6. — № 10. — P. 5823−5832.
- Shimaoka Y. t Hidaka YM Okumura M. et al. Serum concentrations of soluble Fas in patients with autoimmune thyroid diseases. // Thyroid. 1998. — Vol. 8. -№ 1. — P. 43−47.
- Skubitz K.M., Khalil A. Campbell K.D. et al. CD50 (ICAM-3) is phosphorylated on tyrosine and is associated with tyrosyne kinase activity in human neutrophils. //J. Immunol.- 1995.-Vol. 154.-P. 2888−2895.
- Suda Т., Hashimoto H., Tanaka M. et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas-ligand blocks the killing. // J. Exp. Med. 1997. — Vol. 186. — P. 2045−2050.
- Sun L., Adebanjo O.A., Moonga B.S. et al. CD38/ADP-ribosyl cyclase: A new role in the regulation of osteoclastic bone resorption. // J. Cell. Biol. 1999. — Vol. 146.-P. 1161−1172.
- Tokano Y., Miyake S., Kayagaki N. et al. Soluble Fas in patients with systemic Lupus Erythematosus. //J. Clin. Immunol. 1996. — Vol. 16. — P. 261−265.
- Tortorella C" Sac со R., Orlando P. et al. slCAM-1, sCD95 and sCD95L levels in chronic liver diseases of different etiology. // Immunopharmacol. Immuno-toxicol. 2000. — Vol. 22. — № 1. — P. 19−33.
- Toyoda M., Kakizaki S., Horiguchi N. et al. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C. // Liver. 2000. — Vol. 20. — № 4. — P. 305−311.
- Toyozaki Т., Hiroe M., Saito T. et al. Levels of soluble Fas in patients with myocarditis, heart failure of unknown origin, and in healthy volunteers. // Am. J. Cardiol. 1998. — Vol. 81. — № 6. — P. 798−800.
- Tsai S.L., Liaw Y.F., Yeh C.T. et al. Cellular immune response in patients with dual infection of hepatitis В and С viruses: dominant role of hepatitis С virus. // Hepatology. 1995. — Vol. 21. — № 4. — P. 908−912.
- Turowski G., Gociski I., Gieracka D. et al. Soluble class HLA antigens in serum of patients with brain tumors. II Pol. Merkuriusz. Lek. 1996. — Vol. 1. — № 6.-P. 410−411.
- Ueno Т., Toi M., Tominaga T. et al. Circulating soluble Fas concentration in breast cancer patients. // Clin. Cancer Res. 1999. — Vol. 5. — № 11. — P. 35 293 533.
- Umar S., Malavasi F., Mehta K. Post-translational modification of CD38 pro-teininto a high molecular weight form alters its catalytic propeties. // J. Biol. Chem. 1996. — Vol. 271. — P. 15 922−15 927.
- Van Lopik Т., Bijl M., Hart M. et al. Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse. // J. Rheumatol. 1999. — Vol. 26. — № 1. — P. 60−67.
- Volpes R., Van den Oord J.J., Desmet V.J. Vascular adhesion molecules in acute and chronic liver inflammation. // Hepatology. 1992. — Vol. 15. — P. 269 275.
- Walczak H., Krammer P. The CD95 (АРО-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems. // Experimental Cell Research. 2000. — Vol. 256. — P. 5866.
- Wolf R.E., Adamashvili I.M., Gelder F.B. et al. Soluble HLA-I in rheumatic diseases. // Hum. Immunol. 1998. — Vol. 59. — № 10. — P. 644−649.
- Woska J.R., Morelock M.M. Durham D.J. et al. Molecular comparison of soluble intercellular adhesion molecule (slCAM)-1 and slCAM-3 binding to Lymphocyte Function-associated Antigen-1. // J. Biol. Chem. 1998. — Vol. 273. — № 8. — P. 4725−4733.
- Yashina T.L., Favorov M.O., Khudyakov Y.E. et al. Detection of hepatitis G Virus (HGV) RNA: Clinical characteristics of acute HGV infection. II J. of Infec. Dis. 1997. — Vol. 175. — P. 1302−1307.
- Yoshioka К., Kakumu С., Hayashi H. et al. Anti-hepatitis С antibodies in patients with chronic non-A, non-B hepatitis: relation to desease progression and effect of interferon alpha. // Am. J. Gastroenerol. 1991. — Vol. 86. — P. 14 951 499.
- Zavazava N. Soluble HLA class I molecules: biological significance and clinical implications. // Mol. Med. Today. 1998. — Vol. 4. — № 3. — P. 116−121.
- Zavazava N., Kronke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. // Nature Med. 1996. — Vol. 2. — P. 10 051 007.